Berkay Kilic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Berkay Kilic has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Burak Ilhan
Department of Surgery, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Türkiye
8 shared publications - Hasan Karanlik
Department of Surgical Oncology, Istanbul University, Institute of Oncology, Istanbul, Turkiye; SENATURK Senology Academy, Istanbul, Turkiye
7 shared publications Burak İlHan
Istanbul University, Istanbul Faculty of Medicine
5 shared publications- Süleyman Bademler
Department of Surgery, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye
5 shared publications - Muhammed Zubeyr Ucuncu
Department of Anesthesia, Vocational School of Health Services, Istanbul Gelisim University, 34310 Istanbul, Türkiye
4 shared publications Nihat Aksakal
Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
4 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4138
Correction: İlhan et al. Exploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer. Int. J. Mol. Sci. 2025, 26, 8944
The following reference [45] has been retracted and should be replaced from the original publication
- 6 May 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 4138
Open AccessCorrection: İlhan et al. Exploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer. Int. J. Mol. Sci. 2025, 26, 8944
The following reference [45] has been retracted and should be replaced from the original publication
- Open Access
- 30 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (5) , e47123
Feasibility of single-stage direct-to-implant subpectoral breast reconstruction following neoadjuvant chemotherapy for locally advanced breast cancer
Breast reconstruction is increasingly requested in breast cancer surgery, particularly among young women. However, the criteria for its feasibility need to be more clearly defined. This study aimed to compare the surgical safety and long-term oncologic survival outcomes between immediate breast reconstruction (IBR) and conventional mastectomy (CMx) and to determine the main factors affecting recurrence, considering tumor-specific features. The study analyzed 297 patients with locally advanced breast cancer (stage IIB–IIIC and/or axilla positive) who underwent CMx or IBR between January 2015 and December 2021 at Istanbul University, Oncology Institute, and mainly investigated the outcomes of both surgical interventions regarding recurrence and survival rates. The study examined 132 patients who underwent the CMx and 165 with the IBR procedure. Median follow-up was 60.2 months (range, 12–107). On average, younger patients (43.36 vs 50.42, P < .001) and patients with relatively early-stage tumors ( P = .007, for cT and P = .004, for cN) underwent the IBR procedure more often compared with CMx. There was no difference between the 2 groups regarding other tumor-specific characteristics, receptor profiles, regimens of neoadjuvant chemotherapy, response to neoadjuvant chemotherapy, and adjuvant therapies ( P > .05 for each comparison). The definitive pT stage had the highest risk for local recurrence, with a 3.2-fold increased risk independent of the type of surgery performed ( P < .001, 3.22 (1.56–6.66)). However, no difference was between the IBR and CMx groups regarding local recurrence (84.8% vs 85.6%), distant metastasis (81.2% vs 79.5%), free survival rates, and overall survival (94.95 months vs 93.47 months, P = .916). Immediate breast reconstruction is a safe and feasible approach in patients with locally advanced breast cancer receiving neoadjuvant therapy compared to CMx alone, as it does not affect recurrence rates and survival.
- 30 January 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (5) , e47123
Open AccessFeasibility of single-stage direct-to-implant subpectoral breast reconstruction following neoadjuvant chemotherapy for locally advanced breast cancer
Breast reconstruction is increasingly requested in breast cancer surgery, particularly among young women. However, the criteria for its feasibility need to be more clearly defined. This study aimed to compare the surgical safety and long-term oncologic survival outcomes between immediate breast reconstruction (IBR) and conventional mastectomy (CMx) and to determine the main factors affecting recurrence, considering tumor-specific features. The study analyzed 297 patients with locally advanced breast cancer (stage IIB–IIIC and/or axilla positive) who underwent CMx or IBR between January 2015 and December 2021 at Istanbul University, Oncology Institute, and mainly investigated the outcomes of both surgical interventions regarding recurrence and survival rates. The study examined 132 patients who underwent the CMx and 165 with the IBR procedure. Median follow-up was 60.2 months (range, 12–107). On average, younger patients (43.36 vs 50.42, P < .001) and patients with relatively early-stage tumors ( P = .007, for cT and P = .004, for cN) underwent the IBR procedure more often compared with CMx. There was no difference between the 2 groups regarding other tumor-specific characteristics, receptor profiles, regimens of neoadjuvant chemotherapy, response to neoadjuvant chemotherapy, and adjuvant therapies ( P > .05 for each comparison). The definitive pT stage had the highest risk for local recurrence, with a 3.2-fold increased risk independent of the type of surgery performed ( P < .001, 3.22 (1.56–6.66)). However, no difference was between the IBR and CMx groups regarding local recurrence (84.8% vs 85.6%), distant metastasis (81.2% vs 79.5%), free survival rates, and overall survival (94.95 months vs 93.47 months, P = .916). Immediate breast reconstruction is a safe and feasible approach in patients with locally advanced breast cancer receiving neoadjuvant therapy compared to CMx alone, as it does not affect recurrence rates and survival.
- Open Access
- 14 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8944
Exploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer
Early detection of breast cancer (BC) remains a challenge despite advances in screening, leading to poor prognosis in late-stage disease. Circulating microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for early diagnosis. The study aimed to evaluate the diagnostic utility of serum miR-197-3p, miR-1236, and miR-1271 levels in distinguishing BC patients from healthy individuals. Serum samples from 92 BC patients and 31 healthy controls were analyzed. Total RNA was extracted, and miRNA expression levels were quantified using quantitative real-time PCR (qRT-PCR). Expression differences were assessed using the ΔCt method. Receiver Operating Characteristic (ROC) curve analysis evaluated diagnostic performance. Serum miR-197-3p levels were significantly upregulated (fold change = 8.939, p = 0.0048), while miR-1236 was downregulated (fold change = 0.112, p = 0.0029) in BC patients. miR-1271 showed no significant association. miR-1236 demonstrated superior diagnostic performance (AUC = 0.731, sensitivity = 80.7%, specificity = 51.3%) compared to miR-197-3p (AUC = 0.667, sensitivity = 67.0%, specificity = 45.6%). The combination of miR-197-3p and miR-1236 improved diagnostic accuracy (AUC = 0.842, CI: 0.764–0.936). Serum miR-197-3p and miR-1236 hold promise as complementary biomarkers for early BC detection. Larger multicenter studies are warranted to validate their clinical utility.
- 14 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8944
Open AccessExploratory Analysis of Circulating Serum miR-197-3p, miR-1236, and miR-1271 Expression in Early Breast Cancer
Early detection of breast cancer (BC) remains a challenge despite advances in screening, leading to poor prognosis in late-stage disease. Circulating microRNAs (miRNAs) have emerged as promising non-invasive biomarkers for early diagnosis. The study aimed to evaluate the diagnostic utility of serum miR-197-3p, miR-1236, and miR-1271 levels in distinguishing BC patients from healthy individuals. Serum samples from 92 BC patients and 31 healthy controls were analyzed. Total RNA was extracted, and miRNA expression levels were quantified using quantitative real-time PCR (qRT-PCR). Expression differences were assessed using the ΔCt method. Receiver Operating Characteristic (ROC) curve analysis evaluated diagnostic performance. Serum miR-197-3p levels were significantly upregulated (fold change = 8.939, p = 0.0048), while miR-1236 was downregulated (fold change = 0.112, p = 0.0029) in BC patients. miR-1271 showed no significant association. miR-1236 demonstrated superior diagnostic performance (AUC = 0.731, sensitivity = 80.7%, specificity = 51.3%) compared to miR-197-3p (AUC = 0.667, sensitivity = 67.0%, specificity = 45.6%). The combination of miR-197-3p and miR-1236 improved diagnostic accuracy (AUC = 0.842, CI: 0.764–0.936). Serum miR-197-3p and miR-1236 hold promise as complementary biomarkers for early BC detection. Larger multicenter studies are warranted to validate their clinical utility.
- Open Access
Is It Possible to Accurately Evaluate the Tumor Bed After Neoadjuvant Chemotherapy Using a 14G Tru-Cut Biopsy?
Background/Objectives: Accurately identifying residual disease in the breast following neoadjuvant systemic therapy (NST) is a critical aspect of treatment planning. While surgery remains the standard treatment, its omission may be considered in exceptional responders. However, this strategy is still under investigation and carries local and distant recurrence risks. No definitive method currently exists to confirm pathologic complete response (pCR) after NST. This study evaluates the reliability of ultrasound-guided 14G Tru-Cut biopsy in assessing post-NST disease status. Methods: Data from 204 breast cancer patients who underwent ultrasound-guided 14G Tru-Cut biopsy before surgery at Istanbul University Oncology Institute (March 2015–May 2024) were analyzed. Concordance between Tru-Cut biopsy and final pathology was assessed, along with diagnostic accuracy parameters, including false-negative rate (FNR), accuracy, negative predictive value (NPV), and positive predictive value (PPV). Results: The median patient age was 45 years (range: 26–86). The median initial tumor size was 32 mm, reducing to 10 mm post-treatment. Pathologic complete response (pCR) was 33.8% in surgical specimens and 40.7% in biopsy samples. Biopsy misdiagnosed 15 patients, with an overall FNR of 11.1% and accuracy of 92.2% (95% CI, 7.1–18.1%; 95% CI, 87.6–95.5%). Among patients with radiologic complete response (rCR) (n = 99), FNR was 25.8%, and accuracy was 92.1%. The best outcomes were in the rCR and Tru-Cut pCR subgroup, with an FNR of 5.9% and accuracy of 95.6%. In triple-negative breast cancer patients, FNR was 5%, and an accuracy was 97.4%. Conclusions: Although obtaining eight or more samples with a 14G Tru-Cut biopsy after NST is insufficient to alter clinical practice for detecting residual disease, the promising results observed in the rCR and Tru-Cut pCR subgroups suggest its potential role in guiding treatment strategies.
Open AccessIs It Possible to Accurately Evaluate the Tumor Bed After Neoadjuvant Chemotherapy Using a 14G Tru-Cut Biopsy?
Background/Objectives: Accurately identifying residual disease in the breast following neoadjuvant systemic therapy (NST) is a critical aspect of treatment planning. While surgery remains the standard treatment, its omission may be considered in exceptional responders. However, this strategy is still under investigation and carries local and distant recurrence risks. No definitive method currently exists to confirm pathologic complete response (pCR) after NST. This study evaluates the reliability of ultrasound-guided 14G Tru-Cut biopsy in assessing post-NST disease status. Methods: Data from 204 breast cancer patients who underwent ultrasound-guided 14G Tru-Cut biopsy before surgery at Istanbul University Oncology Institute (March 2015–May 2024) were analyzed. Concordance between Tru-Cut biopsy and final pathology was assessed, along with diagnostic accuracy parameters, including false-negative rate (FNR), accuracy, negative predictive value (NPV), and positive predictive value (PPV). Results: The median patient age was 45 years (range: 26–86). The median initial tumor size was 32 mm, reducing to 10 mm post-treatment. Pathologic complete response (pCR) was 33.8% in surgical specimens and 40.7% in biopsy samples. Biopsy misdiagnosed 15 patients, with an overall FNR of 11.1% and accuracy of 92.2% (95% CI, 7.1–18.1%; 95% CI, 87.6–95.5%). Among patients with radiologic complete response (rCR) (n = 99), FNR was 25.8%, and accuracy was 92.1%. The best outcomes were in the rCR and Tru-Cut pCR subgroup, with an FNR of 5.9% and accuracy of 95.6%. In triple-negative breast cancer patients, FNR was 5%, and an accuracy was 97.4%. Conclusions: Although obtaining eight or more samples with a 14G Tru-Cut biopsy after NST is insufficient to alter clinical practice for detecting residual disease, the promising results observed in the rCR and Tru-Cut pCR subgroups suggest its potential role in guiding treatment strategies.
- Open Access
- 25 March 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (1) , 76-85
Long-term oncologic safety of one-stage direct-to-implant immediate breast reconstruction without the use of acellular dermal matrix
Aim: This study aimed to evaluate the oncologic safety of direct-to-implant immediate breast reconstruction without the use of an acellular dermal matrix (ADM) or mesh following nipple-sparing and skin-sparing mastectomy in patients with primary breast cancer. Materials and Methods: The medical records of 175 patients who underwent one-stage direct-to-implant breast reconstruction following mastectomy at the Istanbul University Oncology Institute between 2014 and 2022 were retrospectively reviewed. The primary objective was to assess the oncologic safety, including locoregional recurrence, distant metastasis, and survival outcomes. The secondary objective was to evaluate reconstruction-related complications. Results: The median age of the patients was 44 years (range: 25-74), with a median follow-up period of 53 months (range: 19-101). HR+/HER2-, HR+/HER2+, and pure HER2+ subtypes were observed in 101 patients (57.7%), 26 (14.9%), 23 (13.%), respectively. Triple-negative breast cancer was present in 16 patients (9.1%). Neoadjuvant chemotherapy was administered to 87 patients (49.7%), with a pathological complete response (pCR) rate of 17.2%. Skin necrosis (9.1%) and capsular contracture (8.6%) were the most common complications, with implant loss occuring in seven patients. Locoregional recurrence and distant metastasis rates were 9.7% and 13.1%, respectively. The five-year locoregional recurrence-free survival and distant metastasis-free survival rates were 95.4% and 90.3%. Additionally, 83.5% of patients reported their satisfaction as "excellent" or "good." Conclusion: One-stage direct-to-implant immediate breast reconstruction without the use of an acellular dermal matrix or mesh is oncologically safe, with acceptable complication rates, making it a viable alternative to two-stage breast reconstruction or conventional mastectomy.
- 25 March 2025
- Published by Turkish Journal of Clinics and Laboratory in TURKISH JOURNAL of CLINICS and LABORATORY
- Vol. 16 (1) , 76-85
Open AccessLong-term oncologic safety of one-stage direct-to-implant immediate breast reconstruction without the use of acellular dermal matrix
Aim: This study aimed to evaluate the oncologic safety of direct-to-implant immediate breast reconstruction without the use of an acellular dermal matrix (ADM) or mesh following nipple-sparing and skin-sparing mastectomy in patients with primary breast cancer. Materials and Methods: The medical records of 175 patients who underwent one-stage direct-to-implant breast reconstruction following mastectomy at the Istanbul University Oncology Institute between 2014 and 2022 were retrospectively reviewed. The primary objective was to assess the oncologic safety, including locoregional recurrence, distant metastasis, and survival outcomes. The secondary objective was to evaluate reconstruction-related complications. Results: The median age of the patients was 44 years (range: 25-74), with a median follow-up period of 53 months (range: 19-101). HR+/HER2-, HR+/HER2+, and pure HER2+ subtypes were observed in 101 patients (57.7%), 26 (14.9%), 23 (13.%), respectively. Triple-negative breast cancer was present in 16 patients (9.1%). Neoadjuvant chemotherapy was administered to 87 patients (49.7%), with a pathological complete response (pCR) rate of 17.2%. Skin necrosis (9.1%) and capsular contracture (8.6%) were the most common complications, with implant loss occuring in seven patients. Locoregional recurrence and distant metastasis rates were 9.7% and 13.1%, respectively. The five-year locoregional recurrence-free survival and distant metastasis-free survival rates were 95.4% and 90.3%. Additionally, 83.5% of patients reported their satisfaction as "excellent" or "good." Conclusion: One-stage direct-to-implant immediate breast reconstruction without the use of an acellular dermal matrix or mesh is oncologically safe, with acceptable complication rates, making it a viable alternative to two-stage breast reconstruction or conventional mastectomy.
- Open Access
- 3 March 2025
- Published by The European Research Journal in The European Research Journal
- Vol. 11 (2) , 260-269
Totally implantable venous access devices: A fifteen-year single-center experience
Objectives: Totally implantable venous access devices (TIVADs) are frequently used in cancer patients, offering significant comfort and advantages. This study aims to evaluate the outcomes of patients who underwent port catheter placement. Methods: Data from 3,774 patients who underwent venous port catheter placement between 2007 and 2022 were reviewed. Demographic information, primary diagnoses, port placement locations, number of punctures, complications, and reasons for removal were recorded. Results: The median age of the patients was 54 years (range: 18-86 years). Catheters were placed on the right side in 3,667 patients (97.2%). The most commonly used vessel was the right subclavian vein, accessed in 2,494 patients (66.1%). Complication rates were observed as follows: femoral vein (40%), brachial vein (20%), subclavian vein (12.1%), internal jugular vein (9.9%), and external jugular vein (6.5%). The complication rate following a single puncture was 7.4%, compared to 16.1% for multiple punctures, showing a significant increase with the number of punctures (P=0.03). The most common early complication in 142 (3.8%) patients was arterial puncture with bleeding or hematoma, while the most common late complication was catheter infection of 1.4% (n=54). Conclusions: Venous port catheter placement is generally safe, with the right subclavian vein being the most commonly used site. Ultrasound-guided placement reduces complications, which are more frequent with multiple punctures and left-side placements. Early complications like arterial puncture were more common, while late complications were primarily catheter infection.
- 3 March 2025
- Published by The European Research Journal in The European Research Journal
- Vol. 11 (2) , 260-269
Open AccessTotally implantable venous access devices: A fifteen-year single-center experience
Objectives: Totally implantable venous access devices (TIVADs) are frequently used in cancer patients, offering significant comfort and advantages. This study aims to evaluate the outcomes of patients who underwent port catheter placement. Methods: Data from 3,774 patients who underwent venous port catheter placement between 2007 and 2022 were reviewed. Demographic information, primary diagnoses, port placement locations, number of punctures, complications, and reasons for removal were recorded. Results: The median age of the patients was 54 years (range: 18-86 years). Catheters were placed on the right side in 3,667 patients (97.2%). The most commonly used vessel was the right subclavian vein, accessed in 2,494 patients (66.1%). Complication rates were observed as follows: femoral vein (40%), brachial vein (20%), subclavian vein (12.1%), internal jugular vein (9.9%), and external jugular vein (6.5%). The complication rate following a single puncture was 7.4%, compared to 16.1% for multiple punctures, showing a significant increase with the number of punctures (P=0.03). The most common early complication in 142 (3.8%) patients was arterial puncture with bleeding or hematoma, while the most common late complication was catheter infection of 1.4% (n=54). Conclusions: Venous port catheter placement is generally safe, with the right subclavian vein being the most commonly used site. Ultrasound-guided placement reduces complications, which are more frequent with multiple punctures and left-side placements. Early complications like arterial puncture were more common, while late complications were primarily catheter infection.
- Open Access
- 10 February 2025
- Published by MDPI AG in Preprints.org
Is it Possible to Accurately Evaluate the Tumor Bed After Neoadjuvant Chemotherapy Using a 14-G Tru-cut Biopsy?
Background/Objectives: Accurately detecting residual disease and potentially omitting surgery is crucial in breast cancer treatment. However, no reliable method confirms pathologic complete response (pCR) after neoadjuvant systemic therapy (NST). This study evaluates the reliability of ultrasound-guided 14G trucut biopsy in assessing post-NST disease status. Methods: Data from 204 breast cancer patients who underwent ultrasound-guided 14G trucut biopsy before surgery at Istanbul University Oncology Institute (March 2015–May 2024) were analyzed. Concordance between trucut biopsy and final pathology was assessed, along with diagnostic accuracy parameters, including false-negative rate (FNR), accuracy, negative predictive value (NPV), and positive predictive value (PPV). Results: The median patient age was 45 years (range: 26–86). The median initial tumor size was 32 mm, reducing to 10 mm post-treatment. Pathologic complete response (pCR) was 33.8% in surgical specimens and 40.7% in biopsy samples. Biopsy misdiagnosed 15 patients, with an overall FNR of 11.1% and accuracy of 92.2% (95% CI, 7.1–18.1%; 95% CI, 87.6–95.5%). Among patients with radiologic complete response (rCR) (n = 99), FNR was 25.8%, and accuracy was 92.1%. The best outcomes were in the rCR and trucut pCR subgroup, with an FNR of 5.9% and accuracy of 95.6%. In triple-negative breast cancer patients, FNR was 5%, and accuracy was 97.4%. Conclusions: Although obtaining eight or more samples with a 14G tru-cut biopsy after NST is insufficient to alter clinical practice for detecting residual disease, the promising results observed in the rCR and tru-cut pCR subgroups suggest its potential role in guiding treatment strategies.
- 10 February 2025
- Published by MDPI AG in Preprints.org
Open AccessIs it Possible to Accurately Evaluate the Tumor Bed After Neoadjuvant Chemotherapy Using a 14-G Tru-cut Biopsy?
Background/Objectives: Accurately detecting residual disease and potentially omitting surgery is crucial in breast cancer treatment. However, no reliable method confirms pathologic complete response (pCR) after neoadjuvant systemic therapy (NST). This study evaluates the reliability of ultrasound-guided 14G trucut biopsy in assessing post-NST disease status. Methods: Data from 204 breast cancer patients who underwent ultrasound-guided 14G trucut biopsy before surgery at Istanbul University Oncology Institute (March 2015–May 2024) were analyzed. Concordance between trucut biopsy and final pathology was assessed, along with diagnostic accuracy parameters, including false-negative rate (FNR), accuracy, negative predictive value (NPV), and positive predictive value (PPV). Results: The median patient age was 45 years (range: 26–86). The median initial tumor size was 32 mm, reducing to 10 mm post-treatment. Pathologic complete response (pCR) was 33.8% in surgical specimens and 40.7% in biopsy samples. Biopsy misdiagnosed 15 patients, with an overall FNR of 11.1% and accuracy of 92.2% (95% CI, 7.1–18.1%; 95% CI, 87.6–95.5%). Among patients with radiologic complete response (rCR) (n = 99), FNR was 25.8%, and accuracy was 92.1%. The best outcomes were in the rCR and trucut pCR subgroup, with an FNR of 5.9% and accuracy of 95.6%. In triple-negative breast cancer patients, FNR was 5%, and accuracy was 97.4%. Conclusions: Although obtaining eight or more samples with a 14G tru-cut biopsy after NST is insufficient to alter clinical practice for detecting residual disease, the promising results observed in the rCR and tru-cut pCR subgroups suggest its potential role in guiding treatment strategies.
- 22 January 2025
- Published by Medical Journal of Ankara Training and Research Hospital in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
- Vol. 57 (3) , 93-98
Phyllodes Tumors of the Breast: Recurrence and the Importance of Clinical Follow-up
AIM: Phyllodes tumors, including benign and borderline types, have a substantial potential for recurrence. The objective of this study was to evaluate histologic features that can help predict recurrences, and to emphasize the importance of close follow-up in this regard. MATERIAL AND METHOD: The demographic, clinicopathological characteristics, treatment approaches, and follow-up data of the 64 patients who were treated between 2006 and 2018 at the Istanbul University, Institute of Oncology with the diagnosis of phyllodes tumors were evaluated retrospectively by examining the patient files and pathology records. RESULTS: The median age was 38.8±12.2. The median tumor size was 53.1 mm (range, 11 mm to 210 mm). The phyllodes tumors were classified as follows: benign (n= 36, 56.3%), borderline (n= 11, 17.2%), and malign (n= 17, 26.6%). High mitotic number, cellular pleomorphism, stromal overgrowth, tumoral heterogeneity, and tumor margin irregularity were found to be independent prognostic factors in the development of local recurrence. The common feature of tumor recurrence in the process of benign and borderline phyllodes tumors was tumor margin irregularity. The mean period of recurrence of phyllodes tumors was determined as 29.7 months (range, 10 to 64). In the study, 7 out of 10 recurrences were observed when excision was performed with an insufficient surgical margin of closer than 1 cm, and in three cases when a clear surgical margin was obtained far than 1 cm (p= 0.045). CONCLUSION: Phyllodes tumors were classified as benign, borderline, and malignant. A negative surgical margin of ≥1cm plays a major role in the management of phyllodes tumors. The study may emphasize the importance of close follow-up, given that the recurrence period is short, especially if tumor margin irregularity is detected on definitive pathological examination, even if it is benign or borderline type. Keywords: Phyllodes tumor, breast surgery, margin status
- 22 January 2025
- Published by Medical Journal of Ankara Training and Research Hospital in Ankara Eğitim ve Araştırma Hastanesi Tıp Dergisi
- Vol. 57 (3) , 93-98
Phyllodes Tumors of the Breast: Recurrence and the Importance of Clinical Follow-up
AIM: Phyllodes tumors, including benign and borderline types, have a substantial potential for recurrence. The objective of this study was to evaluate histologic features that can help predict recurrences, and to emphasize the importance of close follow-up in this regard. MATERIAL AND METHOD: The demographic, clinicopathological characteristics, treatment approaches, and follow-up data of the 64 patients who were treated between 2006 and 2018 at the Istanbul University, Institute of Oncology with the diagnosis of phyllodes tumors were evaluated retrospectively by examining the patient files and pathology records. RESULTS: The median age was 38.8±12.2. The median tumor size was 53.1 mm (range, 11 mm to 210 mm). The phyllodes tumors were classified as follows: benign (n= 36, 56.3%), borderline (n= 11, 17.2%), and malign (n= 17, 26.6%). High mitotic number, cellular pleomorphism, stromal overgrowth, tumoral heterogeneity, and tumor margin irregularity were found to be independent prognostic factors in the development of local recurrence. The common feature of tumor recurrence in the process of benign and borderline phyllodes tumors was tumor margin irregularity. The mean period of recurrence of phyllodes tumors was determined as 29.7 months (range, 10 to 64). In the study, 7 out of 10 recurrences were observed when excision was performed with an insufficient surgical margin of closer than 1 cm, and in three cases when a clear surgical margin was obtained far than 1 cm (p= 0.045). CONCLUSION: Phyllodes tumors were classified as benign, borderline, and malignant. A negative surgical margin of ≥1cm plays a major role in the management of phyllodes tumors. The study may emphasize the importance of close follow-up, given that the recurrence period is short, especially if tumor margin irregularity is detected on definitive pathological examination, even if it is benign or borderline type. Keywords: Phyllodes tumor, breast surgery, margin status
- Open Access
- 20 December 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (12) , 14381-14393
The Diagnostic Value of circFBXW7, circABCB10, and circ0103552 Levels in Breast Cancer
Despite advances in cancer treatment, breast cancer (BC) remains one of the most common cancers affecting women worldwide. This study aimed to determine serum circFBXW7, circABCB10, and circ0103552 levels and compare BC patients and healthy controls to investigate their roles in the molecular mechanism of BC and the significance of these circRNAs in BC diagnosis. The study group consisted of 92 patients with BC and 31 healthy controls. Total RNA was isolated from serum samples. Following total RNA, complementary DNA was synthesized from this material. Following complementary DNA analysis, the circRNA levels were analyzed by the qRT-PCR method. Expression levels were evaluated in ΔCt values. High ΔCt values of circFBXW7 and circ0103552 and low ΔCt values of circABCB10 were correlated with BC diagnosis (circFBXW7, p = 0.043, r = 0.183, circ0103552, p < 0.001, r = 0.321, circABCB10, p = 0.001, r = −0.291). According to Fold Change (FC) values, circFBXW7 (FC = 0.30) and circ0103552 (FC = 0.26) showed low expression in the patient group compared to the control group, while circABCB10 (FC = 11.09) showed high expression (p < 0.05, for all comparisons). We think that our study is one of the rare studies investigating the relationship between BC and serum circRNA levels. This study concludes that the significant downregulation of circFBXW7 and circ0103552 and the upregulation of circABCB10 are directly related to the diagnosis of BC and can be used for diagnosis, but further studies are needed to elucidate the molecular mechanism of the relationship between circRNAs and BC.
- 20 December 2024
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 46 (12) , 14381-14393
Open AccessThe Diagnostic Value of circFBXW7, circABCB10, and circ0103552 Levels in Breast Cancer
Despite advances in cancer treatment, breast cancer (BC) remains one of the most common cancers affecting women worldwide. This study aimed to determine serum circFBXW7, circABCB10, and circ0103552 levels and compare BC patients and healthy controls to investigate their roles in the molecular mechanism of BC and the significance of these circRNAs in BC diagnosis. The study group consisted of 92 patients with BC and 31 healthy controls. Total RNA was isolated from serum samples. Following total RNA, complementary DNA was synthesized from this material. Following complementary DNA analysis, the circRNA levels were analyzed by the qRT-PCR method. Expression levels were evaluated in ΔCt values. High ΔCt values of circFBXW7 and circ0103552 and low ΔCt values of circABCB10 were correlated with BC diagnosis (circFBXW7, p = 0.043, r = 0.183, circ0103552, p < 0.001, r = 0.321, circABCB10, p = 0.001, r = −0.291). According to Fold Change (FC) values, circFBXW7 (FC = 0.30) and circ0103552 (FC = 0.26) showed low expression in the patient group compared to the control group, while circABCB10 (FC = 11.09) showed high expression (p < 0.05, for all comparisons). We think that our study is one of the rare studies investigating the relationship between BC and serum circRNA levels. This study concludes that the significant downregulation of circFBXW7 and circ0103552 and the upregulation of circABCB10 are directly related to the diagnosis of BC and can be used for diagnosis, but further studies are needed to elucidate the molecular mechanism of the relationship between circRNAs and BC.
- Open Access
- 10 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1223-1229
Response of mucinous breast carcinoma to neoadjuvant chemotherapy
Background/aim: Mucinous breast carcinoma (MC) is thought to be a favorable-differentiated form of invasive breast cancer and is rarely preferred for neoadjuvant chemotherapy (NAC). The study aimed to define the response of MCs to NAC.Materials and methods: The study reviewed the demographic, clinicopathologic characteristics, management, and follow-up data of 70 patients diagnosed with MC between May 2010 to December 2020 by examining patients’ historical files and oncology records.Results: The median age, tumor size, and follow-up period of patients were respectively 52.9 (range 32 to 87) years, 25.8 (range 8 to 88) mm, and 61.5 (range 18 to 143) months. Out of 70 patients, 45 had conservative surgery, 25 had a mastectomy, and 22 had axillary clearance due to a positive sentinel node biopsy or clinical axilla. Eight patients (11.4%) received NAC. Twenty-one patients (30.0%) received adjuvant chemotherapy whereas almost all patients received hormone therapy. Preoperative core biopsy diagnosis of 4 of 8 patients receiving NAC was unspecified invasive breast carcinoma. NAC was preferred in younger patients, tumors larger in diameter, tumors with initial higher T-stage, especially patients with clinically positive axilla, and tumors with higher Ki-67 index. Despite these preference criteria, both overall mastectomy and axillary clearance rates were significantly higher in these patients. Two local and 5 systemic recurrences were observed in the follow-up period. There was no significant contribution of NAC to survival.Conclusion: The study may conclude that NAC is not sufficiently effective neither in avoiding mastectomy by downsizing the tumor, nor in avoiding axillary clearance in MCs, and no significant benefit on survival could be provided. In addition, the study may emphasize the importance of identifying the subtype of carcinoma, and the significant association between the degree of response to NAC and breast carcinoma subtype.
- 10 December 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1223-1229
Open AccessResponse of mucinous breast carcinoma to neoadjuvant chemotherapy
Background/aim: Mucinous breast carcinoma (MC) is thought to be a favorable-differentiated form of invasive breast cancer and is rarely preferred for neoadjuvant chemotherapy (NAC). The study aimed to define the response of MCs to NAC.Materials and methods: The study reviewed the demographic, clinicopathologic characteristics, management, and follow-up data of 70 patients diagnosed with MC between May 2010 to December 2020 by examining patients’ historical files and oncology records.Results: The median age, tumor size, and follow-up period of patients were respectively 52.9 (range 32 to 87) years, 25.8 (range 8 to 88) mm, and 61.5 (range 18 to 143) months. Out of 70 patients, 45 had conservative surgery, 25 had a mastectomy, and 22 had axillary clearance due to a positive sentinel node biopsy or clinical axilla. Eight patients (11.4%) received NAC. Twenty-one patients (30.0%) received adjuvant chemotherapy whereas almost all patients received hormone therapy. Preoperative core biopsy diagnosis of 4 of 8 patients receiving NAC was unspecified invasive breast carcinoma. NAC was preferred in younger patients, tumors larger in diameter, tumors with initial higher T-stage, especially patients with clinically positive axilla, and tumors with higher Ki-67 index. Despite these preference criteria, both overall mastectomy and axillary clearance rates were significantly higher in these patients. Two local and 5 systemic recurrences were observed in the follow-up period. There was no significant contribution of NAC to survival.Conclusion: The study may conclude that NAC is not sufficiently effective neither in avoiding mastectomy by downsizing the tumor, nor in avoiding axillary clearance in MCs, and no significant benefit on survival could be provided. In addition, the study may emphasize the importance of identifying the subtype of carcinoma, and the significant association between the degree of response to NAC and breast carcinoma subtype.